Oligonucleotide quantification: Flexibility for microfluidic dual hybridization assays

The development of oligo-based therapeutics is a rapidly growing effort, with a need for improved bioanalysis methods for pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Gyros Protein Technologies presents a feasibility study where a hybridization ligand-binding assay was developed and evaluated for the detection of the anti-sense oligonucleotide (ASO) drug casimersen (Amondys 45™) for the treatment of Duchenne muscular dystrophy (DMD) using two labeled oligonucleotide probes with offline incubation followed by an automated microfluidic method. The investigation shows that offline incubation of the sample and capture probe followed by an automated microfluidic method is effective in generating robust data with minimal labor in a short space of time.